COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of XL999 in Patients With Acute Myeloid Leukemia (AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00322673
Recruitment Status : Terminated (Study was terminated due to cardiac toxicities)
First Posted : May 8, 2006
Last Update Posted : February 22, 2010
Information provided by:
Symphony Evolution, Inc.

Brief Summary:
This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL999 when given weekly to patients with relapsed or newly-diagnosed AML. XL999 is a small molecule inhibitor against Flk1/kinase insert domain receptor (KDR), PDGFR, c-Kit, FLT3 and SRC. c-Kit and FLT3 are receptors commonly expressed on AML blasts.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia AML Drug: XL999 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of XL999 Administered Intravenously to Subjects With Acute Myeloid Leukemia
Study Start Date : May 2006
Actual Primary Completion Date : November 2006
Actual Study Completion Date : May 2007

Intervention Details:
  • Drug: XL999
    XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study

Primary Outcome Measures :
  1. Hematologic and cytogenetic response rate [ Time Frame: Inclusion until disease progression ]
  2. Safety and tolerability [ Time Frame: Inclusion until 30 dyas post last treatment ]

Secondary Outcome Measures :
  1. Duration of hematologic response and transfusion independence [ Time Frame: Inclusion until disease progression ]
  2. Progression-free survival [ Time Frame: Inclusion until disease progression ]
  3. Overall survival [ Time Frame: Inclusion until 180-day Follow-up post last treatment or death ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of acute myeloid leukemia (except AML FAB-M3 or acute promyelocytic leukemia [APL]) based on the World Health Organization (WHO) classification of ≥ 20% blasts in the bone marrow or peripheral blood at initial diagnosis (prior to start of standard chemotherapy)
  • ECOG performance status of 0 or 1
  • Subjects with newly-diagnosed AML or subjects with relapsed AML after at least 2 chemotherapy regimens.
  • Adequate liver and renal function
  • Signed informed consent

Exclusion Criteria:

  • Anticancer therapy including chemotherapeutic, biologic, or investigative agents within 30 days of XL999 treatment
  • Hematopoietic stem cell transplantation within the previous 6 weeks
  • Immunosuppressive therapy (eg, cyclosporine, steroids, tacrolimus) for graft-versus-host disease (GvHD) within 30 days prior to the start of XL999
  • The subject has not recovered to grade ≤ 1 or to within 10% of baseline from adverse events due to investigational or chemotherapeutic drugs or stem cell transplantation which were administered > 4 weeks prior to study enrollment
  • Uncontrolled and/or concomitant illness
  • Pregnant or breastfeeding females
  • Known HIV

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00322673

Layout table for location information
United States, California
Eddie Hu
Alhambra, California, United States, 91801
Ronald Paquette
Los Angeles, California, United States, 90095
The Thomas and Dorothy Leavey Cancer Center
Northridge, California, United States, 91328
David Chan
Redondo Beach, California, United States, 90277
United States, Illinois
Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology
Chicago, Illinois, United States, 60611
United States, Indiana
American Health Network of Indiana
Indianapolis, Indiana, United States, 46202
Section of Hematology/Oncology Indiana Cancer Pavilion
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Symphony Evolution, Inc.
Layout table for investigator information
Study Director: Lynne Bui, MD Exelixis
Layout table for additonal information
Responsible Party: Charles W. Finn, PhD, President and CEO, Symphony Evolution, Inc. Identifier: NCT00322673    
Other Study ID Numbers: XL999-207
First Posted: May 8, 2006    Key Record Dates
Last Update Posted: February 22, 2010
Last Verified: February 2010
Keywords provided by Symphony Evolution, Inc.:
acute myeloid leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type